Featured Research

from universities, journals, and other organizations

Once-irrelevant Compound May Have Medical Role In Preventing Diabetes Complications

Date:
January 16, 2008
Source:
American Chemical Society
Summary:
A compound formed during insulin production and once dismissed as irrelevant in diabetes may be a key to preventing the complications that make Type 1 diabetes such a serious disease, according to a new article. Type 1 diabetes, also known as insulin-dependent diabetes, afflicts about 800,000 people in the U.S. alone, sharply increasing their risk of heart attacks, vision loss, kidney failure, and other complications.

A compound formed during insulin production and once dismissed as irrelevant in diabetes may be a key to preventing the complications that make Type 1 diabetes such a serious disease, according to an article scheduled for the Jan. 14 issue of Chemical & Engineering News.

Type 1 diabetes, also known as insulin-dependent diabetes, afflicts about 800,000 people in the U.S. alone, sharply increasing their risk of heart attacks, vision loss, kidney failure, and other complications.

In the article, C&EN Senior Editor Celia Henry Arnaud notes that scientists previously believed that the compound, called C-peptide, had little biological activity and was a useless byproduct of insulin production. In recent years, however, researchers have seen beneficial effects of C-peptide in patients with type 1 diabetes, including improved kidney function, nerve function, and blood flow.

New laboratory research now bolsters that view, suggesting that the compound may work by enhancing the ability of red blood cells to utilize glucose similar to the role that insulin plays for other cell types but only when it binds a metal ion, the article notes.

Clinical studies on the compound, so far inconclusive, may determine if C-peptide can help prevent or delay complications of type 1 diabetes, Arnaud points out. The new research is "a significant contribution to our understanding of C-peptide biology," according to the article.


Story Source:

The above story is based on materials provided by American Chemical Society. Note: Materials may be edited for content and length.


Cite This Page:

American Chemical Society. "Once-irrelevant Compound May Have Medical Role In Preventing Diabetes Complications." ScienceDaily. ScienceDaily, 16 January 2008. <www.sciencedaily.com/releases/2008/01/080114095556.htm>.
American Chemical Society. (2008, January 16). Once-irrelevant Compound May Have Medical Role In Preventing Diabetes Complications. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2008/01/080114095556.htm
American Chemical Society. "Once-irrelevant Compound May Have Medical Role In Preventing Diabetes Complications." ScienceDaily. www.sciencedaily.com/releases/2008/01/080114095556.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins